96 results about "Cell strain" patented technology

This invention relates to a hybridoma cell line that secretes a Cy3.5 monoclonal antibody and its application, belonging to the field of immunoassay. The hybridoma cell line of this invention was deposited on November 12, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 46741. The Cy3.5 monoclonal antibody secreted by this cell line exhibits excellent affinity and sensitivity to Cy3.5, with an IC50 of [missing value]. 50 Reaching 10 ng / mL, the IC50 for Cy5.5 50 An immunoassay product based on this hybridoma cell line, with a concentration of up to 50 ng / mL, can be used for the detection of Cy3.5 and its analogues, providing an efficient detection method and means for the residual detection of Cy3.5.

This invention provides an anti-CD16 antibody, the amino acid sequence of which is selected from SEQ ID NO. 1-3 in the heavy chain CDR region and from SEQ ID NO. 4-6 in the light chain CDR region. This invention belongs to the field of antibodies. It provides a protein sequence of an anti-human CD16 mouse monoclonal antibody, and designs a gene expression base sequence based on the sequenced protein sequence. A stable CHO cell line for recombinant expression of this gene is established. The purified antibody can specifically recognize the human CD16 antigen, and the antibody expression yield is much higher than that of antibodies prepared using traditional hybridoma cells. Furthermore, by replacing mouse IgG1 with rabbit IgG while retaining the variable region, a stable CHO cell line for recombinant expression of the rabbit monoclonal antibody is established. The purified antibody maintains its specific recognition of the human CD16 antigen.

This invention relates to a hybridoma cell line secreting a monoclonal antibody against pendimethalin and its application, belonging to the field of immunoassay. The hybridoma cell line secreting the pendimethalin monoclonal antibody of this invention was deposited on November 12, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 46744. The pendimethalin monoclonal antibody secreted by this hybridoma cell line is used for the analysis and detection of pendimethalin residues in food safety testing. The pendimethalin monoclonal antibody cell line obtained by this invention can be used for immunoassay detection, exhibiting good detection sensitivity and specificity (IC50) for pendimethalin. 50 The value was 1.87 ng / mL.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

The application discloses a kind of SNX9 engineering mitochondria vesicles and its preparation method and application in improving insulin resistance.The application first constructs the vector of overexpression SNX9 gene, transfects cell, obtains stable overexpression SNX9 gene cell strain, culture, collects culture solution, obtains SNX9-MDVs by centrifugal separation;Then mtDNA is extracted from cell and introduced into SNX9-MDVs, to obtain the engineering mitochondria vesicles mtDNA-SNX9-MDVs rich in mtDNA.MtDNA-SNX9-MDVs are used for insulin resistance treatment, and the results show that mtDNA-SNX9-MDVs can effectively increase mitochondrial ATP and mtDNA content, enhance cell antioxidant enzyme activity, reduce ROS, improve mitochondrial network structure, increase the expression of insulin signal pathway related proteins, and show obvious mitochondrial function repair potential and insulin resistance improvement effect.

The application belongs to the technical field of biological medicine, and provides a CXCR4 high expression type iPSC-NK cell with enhanced bone marrow and tumor tissue homing ability, and a preparation method and application thereof. The cell takes pluripotent stem cells as starting cells, overexpresses a membrane-bound IL-15 and IL-15RA fusion protein gene and a CXCR4 receptor gene in the pluripotent stem cells; pluripotent stem cells stably expressing the target gene are obtained, and then iPSC-NK cells are obtained through induction differentiation. The membrane-bound IL-15 and IL-15RA fusion protein gene and the CXCR4 receptor gene are targetedly integrated into a safe harbor site of the induced pluripotent stem cell through a gene editing technology, so as to construct an iPSC cell strain stably expressing key proteins; the function-enhanced iNK cell is obtained through induction differentiation, and exhibits excellent bone marrow and various solid tumor tissue homing ability and persistent immune killing activity.

The application provides a bovine cell gene editing reagent and a construction method and application of a BCO2 gene mutant cell strain, and belongs to the technical field of gene editing. The application provides a bovine cell gene editing reagent, which comprises BE4max SpCas9 V922 Δ mRNA and mRNA containing a target gene target point sequence and gRNA. When the BE4max-SpCas9 V922 Δ mRNA is combined with the gBCO2-1 mRNA to transfect target cells in bovine mammary epithelial cells (Mac-T), the cytosine base editing function in the cells can be normally exerted, and the editing of the bovine BCO2 gene target point is successfully realized.

This invention belongs to the field of biotechnology, providing a mouse anti-human ELL2 monoclonal antibody, its preparation method, and its applications. This invention successfully obtained a 2E1 anti-human ELL2 monoclonal antibody and established a hybridoma cell line capable of stably producing this antibody. The binding affinity (KD) of the obtained 2E1 monoclonal antibody to human ELL2 protein reached the picomolar level (approximately 10^-3 kDa). ‑12 The antibody (M) exhibits extremely strong binding ability. Cross-reactivity tests confirmed that it binds only to human ELL2, and shows no binding signal with highly homologous human ELL1, ELL3, and mouse ELL2, thus completely solving the specificity problem of existing technologies.

The application provides an oxazinane compound, a preparation method, a pharmaceutical composition and application, and a general formula of the oxazinane compound or a pharmaceutically acceptable salt thereof is shown as formula (I). The oxazinane compound has obvious proliferation inhibition effect on cancer cells, especially human head and neck squamous cell carcinoma cell strains HSC4, HSC3, HSC2, CAL33, SCC4 and human glioma cell strain U251, can block the cell cycle, effectively inhibit the phosphorylation level of key proteins in the PI3K / AKT / mTOR pathway at the molecular level, has the potential to be prepared into a new antitumor drug, and has a good market prospect.

The application discloses an aminopyrimidine compound as a protein degradation agent, which is a compound shown in formula (I) or a pharmaceutically acceptable salt, stereoisomer or solvate thereof. The application also discloses a preparation method and medical application of the compound. The compound has FLT3 and CHK1 degradation activity, has proliferation inhibition activity on various tumor cell strains, is effective on various AML mutations such as internal tandem duplication mutations of a near-membrane domain and D835 point mutations of an activation loop in a kinase domain, can overcome drug resistance caused by point mutations in clinic, and can be applied to preparation of an antitumor drug.

The present application relates to a hybridoma cell strain secreting a chlorinated nitrogen aminophenazone monoclonal antibody and its application, and belongs to the technical field of immune detection. The hybridoma cell strain secreting a chlorinated nitrogen aminophenazone monoclonal antibody was preserved in the China General Microbiological Culture Collection Center on April 24, 2026, and the address of the preservation is No. 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No. 46821. The monoclonal antibody secreted by the hybridoma cell strain of the present application has good detection sensitivity (IC 50 Value is 0.27 ng / mL) to chlorinated nitrogen aminophenazone, and can be used for the residual detection of chlorinated nitrogen aminophenazone.

This application provides a rhabdovirus-free Sf9-PT cell line and its applications. This cell line was deposited on March 15, 2023, at the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with accession number CCTCC NO: C202334. The Sf9-PT cell line screened in this application is free from rhabdovirus contamination, allows for high-density culture, exhibits higher viral proliferation levels, and demonstrates more durable viral packaging stability. This cell line can serve as a modified alternative host for the development and commercial production of biological products and vaccines, and can more safely avoid the potential dangers posed by Sf-RV virus contamination.

The application discloses an exosome-based protein delivery system and application thereof. The exosome-based protein delivery system comprises a loading subsystem and / or an unloading subsystem, the polypeptide peptide segment expressed by the nucleotide sequence of the loading subsystem comprises CD63, a connecting peptide, an enterokinase cleavage site and a delivered protein or polypeptide, and the polypeptide peptide segment expressed by the nucleotide sequence of the unloading subsystem comprises CD63, a connecting peptide, enterokinase or enterokinase light chain. The application also constructs a human umbilical cord mesenchymal stem cell strain hUC-MSC CDNF‑exo on November 13, 2024 in the Guangdong Provincial Microbial Culture Collection Center, and the preservation number is GDMCC NO:65478. The human umbilical cord mesenchymal stem cell strain hUC-MSC CDNF‑exo The purpose of delivering CDNF into the cytoplasm of target cells is achieved.

This invention relates to a hybridoma cell line that secretes a monoclonal antibody against azoxystrobin and its application, belonging to the field of immunochemistry. The hybridoma cell line of this invention was deposited on November 12, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 46742, and classified as a monoclonal cell line. The monoclonal antibody secreted by the invented hybridoma cell line exhibits good detection sensitivity (IC50) against azoxystrobin. 50 With a value of 0.049 ng / mL, it can be used for the detection of antimicrobial residues.

The application provides an abnormal prothrombin detection kit and application thereof, and relates to the technical field of in-vitro detection.The application provides a kit for abnormal prothrombin detection, which comprises an abnormal prothrombin antibody, wherein the abnormal prothrombin antibody is derived from a hybridoma cell strain 7E8-4-4-1 of fusion of myeloma cells and mouse B cells, and the hybridoma cell strain 7E8-4-4-1 is preserved in the China General Microbiological Culture Collection Center on October 28, 2025, with a preservation number of CGMCC No.46709.The kit has a large detection range, a small lower limit of detection and high accuracy, and has great application potential in the detection of abnormal prothrombin.

This invention relates to a hybridoma cell line that secretes a monoclonal antibody against Basic Yellow O and its application, belonging to the field of immunoassay. The hybridoma cell line of this invention was deposited on November 12, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 46740. This invention obtains the Basic Yellow O hapten through multiple screenings and experiments, then prepares the Basic Yellow O complete antigen from the hapten, and uses this complete antigen to immunize animals to obtain a hybridoma cell line. The Basic Yellow O monoclonal antibody secreted by this cell line exhibits excellent affinity and sensitivity to Basic Yellow O, with an IC50 value of [missing information - likely a value]. 50 With a concentration of 1 ng / mL, it can be used to prepare immunoassay products for Basic Yellow O, providing an efficient detection method and means for the detection of Basic Yellow O residues in food.

The application relates to the technical field of pharmaceutical chemistry, and discloses a sulfuryl hydrazone compound, a preparation method thereof and anti-tumor application. The compound is synthesized from isatin derivatives and sulfuryl hydrazine through two-step nucleophilic substitution-elimination reaction, has a chemical structure as shown in formula (I), and is characterized by 1H NMR, 13C NMR and HRMS. The sulfuryl hydrazone compound has significant inhibitory activity on A549 (lung cancer), HepG2 (liver cancer) and Hela (cervical cancer) three human cancer cell strains, the value of some compounds is as low as 0.03 micromole / L, the compound can induce cell apoptosis by mediating ROS generation in tumor cells, inhibiting the NF-kappa B signal pathway and activating Caspase-3 activity, and can effectively inhibit cancer cell migration and colony formation. The compound has a mild synthesis process, simple operation and wide substrate applicability, can be used as a potential anti-tumor active ingredient, can be used for preparing drugs for resisting lung cancer, liver cancer, cervical cancer and other tumors, and can provide new candidate compounds and technical support for cancer treatment.

This invention relates to a hybridoma cell line that secretes monoclonal antibodies against BHT and its analogues, belonging to the field of immunoassay technology. The monoclonal antibodies secreted by the hybridoma cell line of this invention exhibit good sensitivity to BHT and its analogues. The monoclonal antibodies of this invention can simultaneously detect BHT, BHA, and TBHQ, and have an IC50 value for BHT. 50 The concentration was 83.08 ng / mL, and the IC50 for BHA was... 50 The concentration was 92.2 ng / mL, and the IC50 for TBHQ was [missing value]. 50 With a concentration of 86.0 ng / mL, the monoclonal antibody of this invention can simultaneously detect trace amounts of BHT, BHA, and TBHQ, and can be used for the residual detection of BHT, BHA, and TBHQ.

The application discloses K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies, hybridoma cell strains thereof and application of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies, sequence information of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies is shown as SEQ NO:1-SEQ NO:56, preservation numbers of the hybridoma cell strains are CCTCC:C2023365, CCTCC:C2023366, CCTCC:C2023367, CCTCC:C2024340, CCTCC:C2024341, CCTCC:C2024342 and CCTCC:C2024343 respectively, the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies provided by the application can be specifically combined with capsular polysaccharide of Klebsiella, are favorable for typing of Klebsiella pneumoniae in clinic, and can prove excellent effects of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies in preventing and treating infection of Klebsiella pneumoniae in in-vivo and in-vitro tests, and the application provides a way for solving problems of Klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance for preventing, diagnosing and treating Klebsiella pneumoniae infection, and has important value for developing a new generation of Klebsiella pneumoniae drugs.

The invention relates to the field of biomedical research, and provides a lung cancer cell strain (H1299) capable of stably and low-expressing Integrin alpha6 protein and a construction method of the lung cancer cell strain (H1299). The preparation method comprises the following steps: designing and synthesizing an shRNA (short hairpin Ribonucleic Acid) sequence for specifically knocking down gene expression aiming at a human Integrin alpha6 gene, forming a double-chain fragment through annealing, and inserting the shRNA sequence into a pLKO.1-puro lentiviral vector by adopting a connection independent cloning (LIC) method, so as to construct a pLKO.1-ITG alpha6-shRNA recombinant plasmid. Furthermore, the recombinant plasmid and lentivirus packaging plasmids psPAX2 and pVSVG are co-transfected to an HEK293T cell by utilizing a lentivirus packaging system, and the lentivirus is produced by packaging. And infecting a target lung cancer cell strain H1299 by using the obtained lentivirus, and then carrying out puromycin resistance screening and continuous subculture to finally obtain the stable and continuous low-expression Integrin alpha6 protein H1299 cell strain. A fluorescence microscope, a real-time fluorescent quantitative PCR (Polymerase Chain Reaction) and an immunoblotting technology are used for verifying that the gene silencing efficiency of the Integrin alpha6 in the cell strain can reach more than 80%. The stable cell strain constructed by the invention provides a reliable and efficient tool cell model for researching the molecular mechanism of the Integrin alpha6 in the processes of occurrence and development, invasion and metastasis, energy metabolism, immune escape and the like of lung cancer, and also provides a new experimental material for screening antitumor drugs targeting the Integrin alpha6.

This invention discloses a hybridoma cell line that secretes a canine OSMRβ monoclonal antibody and its applications. The monoclonal antibody binds to the extracellular terminal region of canine OSMRβ cells, exhibiting high affinity and specificity, and can be used for immunofluorescence detection, flow cytometry, and ELISA. The monoclonal antibody of this invention shows significant application potential in the development of canine OSMRβ detection reagents and diagnostic reagents for diseases and symptoms related to canine OSMRβ.

The application discloses a preparation method and application of cell membrane-derived nanovesicles with specific targeting tumor and metastasis inhibition. The CD82 overexpression lung epithelial cell HBE cell strain is constructed through gene engineering, cell membranes are extracted in vitro, AS1411 aptamer is modified, and a chemotherapeutic drug, doxorubicin (DOX), is loaded to prepare an engineered nanovesicle drug delivery system. The engineered nanovesicle drug delivery system prepared by the application is proved to have multiple effects such as targeting triple-negative breast cancer, inhibiting metastasis and inducing triple-negative breast cancer cell apoptosis through in-vitro and in-vivo experiments. The application fills the gap of the extracellular vesicles as a drug carrier, and provides a new thought and scientific basis for the clinical treatment of triple-negative breast cancer.

The present application relates to the field of cell culture, in particular to a culture and screening method of MDCK monoclonal cell strain, and provides a culture method of MDCK monoclonal cell strain, comprising the following steps: S1, culturing pretreated cells to logarithmic phase; S2, inoculating the cells in logarithmic phase in S1 to the first culture carrier after diluting to a concentration of 1 cell / 100 μL; S3, inoculating the single cell colony in the first culture carrier in S2 to the second culture carrier after digestion, until the cell fusion degree reaches 70-80%, and obtaining the MDCK monoclonal cell strain. The present application realizes early detection without expanding the monoclonal cells to T75 culture flask, avoids the step of gradually expanding and culturing for 7-10 days in the traditional method, greatly shortens the overall screening period from the original 14-21 days, and can quickly match the demand of H3N2 virus variation for highly adaptive cell strains.

The application provides a hybridoma cell strain secreting a monoclonal antibody against a alginate mannuronic acid tetrasaccharide epitope, a monoclonal antibody and application. In order to enhance the immunogenicity of the mannuronic acid tetrasaccharide, a glycoconjugate KLH-1 is used as an immunogen to inject and immunize a mouse, so that the mouse is stimulated to produce a specific immune response against the mannuronic acid tetrasaccharide epitope, then spleen cells of the immunized mouse are fused with myeloma cells, and after screening, an initial hybridoma cell strain is obtained; then after subcloning and specific screening, a hybridoma cell strain capable of stably secreting a monoclonal antibody of the target mannuronic acid tetrasaccharide epitope in alginate is obtained, and a monoclonal ascites antibody is further obtained. The monoclonal ascites antibody shows specific recognition and combination ability for pseudomonas aeruginosa, and the combination activity is related to the expression level of alginate on the surface of the bacteria. Therefore, the monoclonal ascites antibody can be used as a precise detection and diagnosis tool for pseudomonas aeruginosa, and can also be applied to the antibacterial treatment of pseudomonas aeruginosa infection.

This application discloses a method for screening single B cells. The method provided in this application uses magnetic beads coated with IL-6 antigen, combined with fluorescently labeled secondary antibody, and employs droplet microfluidic technology to rapidly sort B cells. The obtained IL-6 positive B cells are then directly cultured, and the generated antibodies are subjected to ELISA and IL-6 antigen-antibody affinity detection to obtain the target cell line. The entire process is greatly simplified and the workload is significantly reduced.

This invention relates to a hybridoma cell line, its secreted mouse anti-human Hb monoclonal antibody, and its applications, belonging to the fields of immunology and in vitro diagnostics. A hybridoma cell line is deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: C2023339. The hybridoma cell line prepared by this invention can stably secrete mouse anti-human Hb monoclonal antibodies. The mouse anti-human Hb monoclonal antibodies secreted by the hybridoma cell line have characteristics such as small batch-to-batch variability and high affinity. The detection kit prepared using the mouse anti-human Hb monoclonal antibody secreted by the hybridoma cell line of this invention has a wide linear range, high specificity, and good positive / negative differentiation.

This invention discloses an enhancer that regulates chicken PGC-1α gene expression and its applications, belonging to the field of bioengineering. The nucleotide sequence of the enhancer is shown in SEQ ID NO: 1. This invention further discloses biomaterials containing this enhancer and a method for preparing cell lines with the enhancer knocked out. A dual-luciferase reporter gene system confirmed its significant activity in DF1 and ICP2 cells. Knocking out this enhancer downregulates PGC-1α gene expression in chicken preadipocytes, significantly promoting cell differentiation and lipid droplet formation. This enhancer can be used to prepare biological agents that regulate PGC-1α gene expression levels and chicken preadipocyte differentiation. It can also be applied to the genetic improvement of chicken fat traits and to the preparation of models for studying related gene function and cell differentiation mechanisms. This invention provides new targets and technical support for improving chicken fat traits.

The present application relates to a hybridoma cell strain secreting a dimethomorph monoclonal antibody and its application, and belongs to the field of food safety immune detection. The hybridoma cell strain DBL secreting a dimethomorph monoclonal antibody has been preserved in the China General Microbiological Culture Collection Center on April 17, 2025, with a preservation number of CGMCC No. 46510, a preservation address of No. 3, Beichen West Road, Chaoyang District, Beijing, and a classification designation of a monoclonal cell strain. The dimethomorph monoclonal antibody obtained by using the strain to secrete can be used for the analysis and detection of dimethomorph residues in food safety detection. The dimethomorph monoclonal antibody cell strain obtained by the present application can be used for immune analysis and detection, and has good detection sensitivity (IC 50 value of 104.49 ng / mL) for dimethomorph.